Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Amlodipine/atorvastatin pill effective in diabetics with hypertension and dyslipidemia

Sep. 7, 2004

New data on the pharmacokinetics of Oralin in type 1 diabetes

Sep. 7, 2004

Novel DPP-IV inhibitor BMS-477118 shows potential for type 2 diabetes

Sep. 7, 2004

New prostanoid EP4 agonists and their use in osteoporosis and other bone disorders

Sep. 7, 2004

University of Kansas and Bioqual researchers describe a novel, orally active male contraceptive

Sep. 6, 2004

Icagen receives milestone payment for ICA-17043 progress

Sep. 6, 2004

PBI-1402 has confirmed activity on red blood cell progenitors

Sep. 6, 2004

Schering AG commences Angeliq roll-out across Europe

Sep. 6, 2004

Raloxifene not associated with an increase in hot flushes in postmenopausal women

Sep. 6, 2004

Exenatide NDA accepted for review

Sep. 3, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...